Chronic Lymphocytic Leukemia/Small-Cell Lymphoma: 6-Year Follow-Up on SEQUOIA and ALPINE LTE1

In this segment, experts review 6-year follow-up data from the SEQUOIA and ALPINE studies in CLL and SLL, with a focus on efficacy, safety, and treatment selection in the modern era.

Ian Flinn, MD, PhD; and Danielle Brander, MD, reflect on the key long-term findings from the SEQUOIA trial, with particular emphasis on durability of response and outcomes in high-risk patient populations.

Experts discuss the promising long-term results of zanubrutinib for high-risk CLL patients, emphasizing the importance of upfront biomarker testing.

Long-term follow-up data on BTK inhibitors reassures patients about safety and efficacy, guiding treatment decisions for chronic conditions.

Experts discuss the complexities of treatment regimens for CLL, focusing on MRD's role and the impact on patient outcomes.

Experts discuss the complexities of treatment regimens for CLL, focusing on MRD's role and the impact on patient outcomes.

Experts discuss the evolving role of BTK inhibitors and venetoclax in treatment regimens, emphasizing the need for personalized therapy durations.

Experts discuss the evolving role of BTK inhibitors and venetoclax in treatment regimens, emphasizing the need for personalized therapy durations.